Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12391301 | 0.88 | GPR35 (0.51) | MAPTL3MBTL1MEN1KMT2ALMNA | |
| SCHEMBL2334316 | 0.83 | LMNA (0.57) | IDO1CXCR3MAPTCLK2DYRK1A | |
| SCHEMBL12584121 | 0.80 | CCR2 (0.55) | MEN1KMT2ALMNA | |
| SCHEMBL2332245 | 0.76 | MAPT (0.57) | CXCR3MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL17477618 | 0.74 | HPGD (0.41) | KMT2ALMNA | |
| SCHEMBL15079330 | 0.71 | CCR2 (0.51) | — | |
| SCHEMBL289221 | 0.71 | CAPN1 (0.54) | MAPTMEN1KMT2ALMNAATM | |
| SCHEMBL17477632 | 0.71 | L3MBTL1 (0.40) | L3MBTL1 | |
| SCHEMBL9685245 | 0.71 | MAPT (0.58) | IDO1CXCR3MAPTL3MBTL1KMT2A | |
| SCHEMBL17477638 | 0.71 | GPR35 (0.41) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2534155-B1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENT MANAGEMENT PTY LTD (AU) | 2018-04-11 | — | — | EP | disclosed |
| US-9540387-B2 | Substituted imidazo[1,2-d]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2017-01-10 | — | — | US | disclosed |
| CN-102844318-B | Be used for the treatment of the compound of respiratory syncytial virus infection | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2016-04-13 | — | — | CN | disclosed |
| US-20160046642-A1 | Compounds for Treating Respiratory Syncytial Virus Infections | BIOTA SCIENT MANAGEMENT (AU) | 2016-02-18 | — | — | US | disclosed |
| US-9163029-B2 | Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20140051697-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-8604034-B2 | Substituted imidazo[1,2-α]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus (RSV) infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2013-12-10 | — | — | US | disclosed |
| CN-102844318-A | Compounds for treating respiratory syncytial virus infections | BIOTA SCIENT MAN | 2012-12-26 | — | — | CN | disclosed |
| EP-2534155-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | Biota Scientific Management Pty Ltd (AU) | 2012-12-19 | — | — | EP | disclosed |
| US-20110207728-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2011-08-25 | — | — | US | disclosed |
| WO-2011094823-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207728-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | FURIN, SQOR, SUCNR1 | IDO1 1643/4885CXCR3 1327/4885MAPT 4436/4885 |
| US-20160046642-A1 | Compounds for Treating Respiratory Syncytial Virus Infections | FURIN, SQOR, SUCNR1 | IDO1 1643/4885CXCR3 1327/4885MAPT 4436/4885 |
| US-20140051697-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | FURIN, SQOR, SUCNR1 | IDO1 1643/4885CXCR3 1327/4885MAPT 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.